Comparison of the Performance of the Infiniti Vision and the Series 20000 Legacy Phacoemulsification Systems

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-03-31

Study Completion Date

2005-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To compare the efficiency of the Infiniti vision system and the Series 20000 Legacy System phacoemulsification units during routine cataract extraction.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cataract Extraction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Legacy 20000

Intervention Type DEVICE

Infinit system

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Cataract
* Eligible for cataract extraction with primary implantation of a posterior chamber IOL
* 2 to 3+ cataract density

Exclusion Criteria

* Preoperative ocular pathology that can affect visual acuity
* Corneal irregularities such as keratoconus, corneal dystrophy, corneal opacities.
* Previous intraocular or corneal surgery.
* Other ocular surgery at the time of the cataract extraction.
* Significant intraoperative intraocular bleeding
* Detached Descemet's membrane
* Implantation of the intraocular lens in the anterior chamber or sulcus

Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Kerry D. Solomon, MD

Role: PRINCIPAL_INVESTIGATOR

Medical University of South Carolina

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MRC-05-002

Identifier Type: -

Identifier Source: org_study_id